$1.35 Billion is the total value of Rock Springs Capital Management LP's 137 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HCA | HCA HOLDINGS INC | $33,114,000 | -1.3% | 430,000 | 0.0% | 2.45% | -12.8% | |
| LLY | LILLY ELI & CO | $21,735,000 | +9.4% | 276,000 | 0.0% | 1.61% | -3.4% | |
| TEVA | TEVA PHARMACEUTICAL INDS LTDadr | $19,841,000 | -6.1% | 395,000 | 0.0% | 1.47% | -17.1% | |
| TMO | THERMO FISHER SCIENTIFIC INC | $14,806,000 | +4.4% | 100,200 | 0.0% | 1.10% | -7.8% | |
| AMGN | AMGEN INC | $14,302,000 | +1.5% | 94,000 | 0.0% | 1.06% | -10.3% | |
| MD | MEDNAX INC | $14,124,000 | +12.1% | 195,000 | 0.0% | 1.05% | -0.9% | |
| TXMD | THERAPEUTICSMD INC | $13,388,000 | +32.8% | 1,575,000 | 0.0% | 0.99% | +17.3% | |
| GLPG | GALAPAGOS NVspon adr | $11,649,000 | +32.6% | 210,000 | 0.0% | 0.86% | +17.1% | |
| PRTA | PROTHENA CORP PLC | $10,768,000 | -15.1% | 308,000 | 0.0% | 0.80% | -25.0% | |
| PRAH | PRA HEALTH SCIENCES INC | $10,565,000 | -2.3% | 253,000 | 0.0% | 0.78% | -13.7% | |
| RTRX | RETROPHIN INC | $9,286,000 | +30.4% | 521,400 | 0.0% | 0.69% | +15.1% | |
| ALKS | ALKERMES PLC | $8,406,000 | +26.4% | 194,500 | 0.0% | 0.62% | +11.7% | |
| MCRB | SERES THERAPEUTICS INC | $7,611,000 | +9.4% | 262,000 | 0.0% | 0.56% | -3.4% | |
| JUNO | JUNO THERAPEUTICS INC | $7,573,000 | +0.9% | 197,001 | 0.0% | 0.56% | -10.8% | |
| BGNE | BEIGENE LTDsponsored adr | $6,705,000 | +1.7% | 225,000 | 0.0% | 0.50% | -10.3% | |
| RTIX | RTI SURGICAL INC | $6,677,000 | -10.3% | 1,860,000 | 0.0% | 0.49% | -20.7% | |
| ATHN | ATHENAHEALTH INC | $6,314,000 | -0.6% | 45,750 | 0.0% | 0.47% | -12.2% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $6,235,000 | +0.3% | 765,001 | 0.0% | 0.46% | -11.3% | |
| NVAX | NOVAVAX INC | $6,198,000 | +40.9% | 852,500 | 0.0% | 0.46% | +24.4% | |
| MGNX | MACROGENICS INC | $6,073,000 | +43.9% | 225,000 | 0.0% | 0.45% | +27.5% | |
| NVDQ | NOVADAQ TECHNOLOGIES INC | $5,461,000 | -11.3% | 555,000 | 0.0% | 0.40% | -21.7% | |
| AVXS | AVEXIS INC | $5,428,000 | +39.6% | 142,758 | 0.0% | 0.40% | +23.3% | |
| CGEN | COMPUGEN LTDord | $5,314,000 | +16.1% | 820,000 | 0.0% | 0.39% | +2.6% | |
| CO | CHINA CORD BLOOD CORP | $5,060,000 | -5.3% | 880,000 | 0.0% | 0.38% | -16.3% | |
| INSYQ | INSYS THERAPEUTICS INC NEW | $4,730,000 | -19.1% | 365,500 | 0.0% | 0.35% | -28.6% | |
| ADRO | ADURO BIOTECH INC | $4,694,000 | -11.7% | 415,000 | 0.0% | 0.35% | -21.8% | |
| XENT | INTERSECT ENT INC | $4,396,000 | -32.0% | 340,000 | 0.0% | 0.32% | -39.9% | |
| AGNPRA | ALLERGAN PLCpfd conv ser a | $4,164,000 | -9.2% | 5,000 | 0.0% | 0.31% | -19.8% | |
| PTLA | PORTOLA PHARMACEUTICALS INC | $4,130,000 | +15.7% | 175,000 | 0.0% | 0.31% | +2.3% | |
| KITE | KITE PHARMA INC | $4,000,000 | +8.9% | 80,000 | 0.0% | 0.30% | -3.9% | |
| OTIC | OTONOMY INC | $3,811,000 | +6.4% | 240,000 | 0.0% | 0.28% | -6.0% | |
| MEDICINES COnote 2.500% 1/1 | $3,549,000 | +4.2% | 3,000,000 | 0.0% | 0.26% | -7.7% | ||
| AIMT | AIMMUNE THERAPEUTICS INC | $3,170,000 | -20.2% | 293,000 | 0.0% | 0.24% | -29.4% | |
| CDTX | CIDARA THERAPEUTICS INC | $2,578,000 | -18.8% | 250,000 | 0.0% | 0.19% | -28.2% | |
| SRPT | SAREPTA THERAPEUTICS INC | $2,498,000 | -2.3% | 131,000 | 0.0% | 0.18% | -13.6% | |
| NVCR | NOVOCURE LTD | $2,501,000 | -19.4% | 214,316 | 0.0% | 0.18% | -28.8% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $2,406,000 | -24.2% | 165,000 | 0.0% | 0.18% | -33.1% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $2,381,000 | +0.2% | 73,000 | 0.0% | 0.18% | -11.6% | |
| NVLS | NIVALIS THERAPEUTICS INC | $2,249,000 | +10.3% | 489,000 | 0.0% | 0.17% | -2.9% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $2,165,000 | +10.6% | 390,000 | 0.0% | 0.16% | -2.4% | |
| GNCA | GENOCEA BIOSCIENCES INC | $1,968,000 | -47.0% | 480,000 | 0.0% | 0.15% | -53.1% | |
| CLVS | CLOVIS ONCOLOGY INC | $1,715,000 | -28.5% | 125,000 | 0.0% | 0.13% | -36.8% | |
| DMTX | DIMENSION THERAPEUTICS INC | $1,628,000 | -23.4% | 271,370 | 0.0% | 0.12% | -32.0% | |
| EGLTQ | EGALET CORP | $1,488,000 | -27.7% | 300,000 | 0.0% | 0.11% | -36.0% | |
| ICPT | INTERCEPT PHARMACEUTICALS IN | $1,427,000 | +11.1% | 10,000 | 0.0% | 0.11% | -1.9% | |
| CHMA | CHIASMA INC | $1,423,000 | -68.5% | 492,500 | 0.0% | 0.10% | -72.2% | |
| ANTH | ANTHERA PHARMACEUTICALS INC | $1,391,000 | -14.6% | 450,000 | 0.0% | 0.10% | -24.3% | |
| SCYX | SCYNEXIS INC | $1,378,000 | -46.2% | 635,000 | 0.0% | 0.10% | -52.3% | |
| CERU | CERULEAN PHARMA INC | $1,325,000 | -21.8% | 625,000 | 0.0% | 0.10% | -31.0% | |
| WRIGHT MED GROUP INCnote 2.000% 2/1 | $919,000 | +2.3% | 1,000,000 | 0.0% | 0.07% | -9.3% | ||
| BLUE | BLUEBIRD BIO INC | $866,000 | +1.9% | 20,000 | 0.0% | 0.06% | -9.9% | |
| OREX | OREXIGEN THERAPEUTICS INC | $711,000 | -23.5% | 1,653,000 | 0.0% | 0.05% | -32.1% | |
| MIRN | MIRNA THERAPEUTICS INC | $639,000 | -2.6% | 150,000 | 0.0% | 0.05% | -14.5% | |
| INFI | INFINITY PHARMACEUTICALS INC | $359,000 | -74.8% | 270,000 | 0.0% | 0.03% | -77.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.